Academic Journal
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors
| العنوان: | Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors |
|---|---|
| المؤلفون: | Valentina Magri, Gianluigi De Renzi, Luca MARINO, Michela De Meo, MARCO SIRINGO, Alain Gelibter, Roberta Gareri, Chiara Cataldi, Giuseppe Giannini, Daniele Santini, chiara nicolazzo, PAOLA GAZZANIGA |
| المساهمون: | Magri, Valentina, DE RENZI, Gianluigi, Marino, Luca, DE MEO, Michela, Siringo, Marco, Gelibter, Alain, Gareri, Roberta, Cataldi, Chiara, Giannini, Giuseppe, Santini, Daniele, Nicolazzo, Chiara, Gazzaniga, Paola |
| سنة النشر: | 2024 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: | CellSearch®, circulating cancer-associated macrophage-like cell, circulating tumor cell, immunotherapy, non-small-cell lung cancer |
| الوصف: | Evidence has been provided that circulating cancer-associated macrophage-like cell (CAM-L) numbers increase in response to chemotherapy, with an inverse trend compared to circulating tumor cells (CTCs). In the era of evolving cancer immunotherapy, whether CAM-Ls might have a potential role as predictive biomarkers of response has been unexplored. We evaluated whether a serial blood evaluation of CTC to CAM-L ratio might predict response to immune checkpoint inhibitors in a cohort of non-small-cell lung cancer patients. At baseline, CTCs, CAM-Ls, and the CTC/CAM-L ratio significantly correlate with both progression-free survival (PFS) and overall survival (OS). The baseline CTC/CAM-L ratio was significantly different in early progressors (4.28 ± 3.21) compared to long responders (0.42 ± 0.47) (p = 0.001). In patients treated with immune checkpoint inhibitors, a CTC/CAM-L ratio ≤ 0.25 at baseline is associated with better PFS and OS. A baseline CTC/CAM-L ratio ≤ 0.25 is statistically significant to discriminate early progressions from durable response. The results of the present pilot study suggest that CAM-Ls together with CTCs could play an important role in evaluating patients treated with cancer immunotherapy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/wos/WOS:001201513300001; journal:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; https://hdl.handle.net/11573/1707559 |
| DOI: | 10.3390/ijms25073752 |
| الاتاحة: | https://hdl.handle.net/11573/1707559 https://doi.org/10.3390/ijms25073752 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.403E452B |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/ijms25073752 |
|---|